First in human nanotherapy brain cancer trial launched at CTRC

March 17, 2015

David Williams is the first human being ever to have a new radiation treatment implanted in the center of his brain tumor.

The technology, developed at the Cancer Therapy & Research Center at The University of Texas Health Science Center at San Antonio, uses tiny radioactive liposomes, or fat particles, only 100 nanometers across, inserted by the thinnest of catheters directly into a tumor. There they remain, radiating only a tiny distance, affecting only the tumor.

Andrew Brenner, M.D., Ph.D., a neuro-oncologist, is leading the clinical trial at the CTRC, and expects to start the second patient on the study within a month.

At his first follow-up appointment Monday, Williams reported feeling great, and said he did not experience the side effects that one normally does after conventional radiation therapy. That technology must send its beams through healthy tissue to reach the tumor, and so must be limited in the amount of radiation it delivers.

"The technology is unique," Dr. Brenner said. "Only we can load the liposomes to these very high radioactivity levels."

The concept was developed by nuclear medicine physician William T. Phillips, M.D., and biochemist Beth A. Goins, Ph.D., in the Department of Radiology; and Ande Bao, Ph.D., a medical physicist and pharmaceutical chemist formerly in the Department of Otolaryngology, all of the School of Medicine at the Health Science Center. They originally thought of trying it in head and neck cancers.

But Dr. Brenner had a different idea.

"I thought it made sense to use it in brain cancer first," he said. "The skull is a rigid structure" and the tissue inside is much less varied, he said, whereas in the neck and other parts of the head there are many different kinds of tissue and lots of moving parts. He worked with neurosurgeon John R. Floyd II, M.D., to apply the first treatment to Mr. Williams on March 10 at University Hospital.

"One of the challenges is how to get the highly radioactive nano liposomes into the brain, and precisely into the tumor," Dr. Floyd said. "Surgical targeting, precision, and delivery became of the utmost importance."

In the past, using a catheter to apply traditional chemotherapy has run into problems because of the catheter design, he said. "To effectively deliver this novel therapy, and improve our surgical targeting, we would need a better catheter. The one we are using is a new design, enabling us to deliver small quantities in precise locations. We are very pleased already with delivery in our first case."

While not all brain tumors are malignant, the glioblastoma is especially deadly. To add to that, as the tumor advances it affects the brain in unpredictable ways, often involving radical shifts in personality and behavior.

"It's a terrible thing for a family to lose a loved one to glioblastoma," Dr. Brenner said. "It's tough to lose them to any cancer, but with the brain tumor you see them change right before your eyes."

The early research was incredibly promising, but to get a cancer drug to the clinical stage and see how it works in patients takes a mountain of work, a pile of money, and usually long years of regulatory processes. This particular project attracted the attention of the CTRC Foundation, which partnered with the Health Science Center to found NanoTx Therapeutics to help move the research into clinical trials.

Working with NanoTx, Dr. Brenner wrote business and scientific proposals, gaining a $2 million grant from the Cancer Prevention and Research Institute of Texas in February.

"It is exceedingly unusual for any major university or cancer center to take a basic science discovery from the lab all the way through the marathon of requirements and hurdles, and to then witness a patient receiving the treatment," said CTRC Director Ian M. Thompson Jr., M.D. "This is a testimony to our dedicated scientists and physicians, to our institution's commitment to major advances in clinical care, and to so many individuals in the San Antonio community who helped make it possible."

It can be hard to explain to desperate family members that not everybody is eligible for a study, and that the study is just that - not a guarantee of cure.

"You never know until you begin the studies how a human being is going to react to a new therapy, and we have to be very careful about how we proceed on that," Dr. Brenner said. And in this case it's not only the therapy that's new, it's how it gets to the tumor.

"The main limitation right now is we have to start with small-sized tumors, until we get a better handle on our delivery methods, to make sure we can cover larger tumors," he said.

Caution is the word on new therapies in general - that's why they go through such an enormous vetting process before they ever get to the first patient.

But Dr. Brenner has a good feeling about this one.

"I don't like to oversell an unproven drug," he said, "but I would like to say the laboratory results were very encouraging. I have evaluated a lot of therapeutics and I have not seen this level of efficacy before."
-end-


University of Texas Health Science Center at San Antonio

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.